ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Ensitrelvir (Zokovea)

Post exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

2 trials are being summarised and will appear here shortly.

CHMP opinion 23 Jun 2026 → EU licence 18 Sept 2026 · Shionogi B.V.
US · FDA approval, new medicine

Ensitrelvir (Xocova)

To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19

Approved 29 May 2026

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.